Trial Profile

A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus recombinant vaccine nonavalent Xiamen Innovax Biotech (Primary) ; Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax
Indications Cervical cancer; Condylomata acuminata
Focus Pharmacodynamics; Therapeutic Use

09 Jul 2026 Results presented in the Xiamen Innovax Biotech media release.
09 Jul 2026 According to a Xiamen Innovax Biotech media release, results from a Phase III trial were publish online in The Lancet Infectious Diseases (DOI: 10.1016/S1473-3099(26)00221-5)
30 Dec 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com